# Efficacy of Favipiravir Against Severe Ebola Virus Disease

> **NCT02662855** · PHASE2 · COMPLETED · sponsor: **Beijing Institute of Pharmacology and Toxicology** · enrollment: 77 (actual)

## Conditions studied

- Ebola Virus Disease

## Interventions

- **OTHER:** WHO-recommended therapies
- **DRUG:** Favipiravir

## Key facts

- **NCT ID:** NCT02662855
- **Lead sponsor:** Beijing Institute of Pharmacology and Toxicology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2015-04
- **Final completion:** 2015-05
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2016-01-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02662855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02662855, "Efficacy of Favipiravir Against Severe Ebola Virus Disease". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02662855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*